Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Molecular Autism

Fig. 2

From: Oxytocin-induced increase in N,N-dimethylglycine and time course of changes in oxytocin efficacy for autism social core symptoms

Fig. 2

Effects of intranasal oxytocin on changes in metabolite concentrations and time-course change in effects of oxytocin. a–c Individual changes from baseline in the natural logarithm of the mode of the probability density function (log-PDFmode) of neutral facial expression intensity. Plots show changes from baseline of log-PDFmode of neutral facial expression intensity in participants administered placebo (a) or oxytocin (b). Among the participants administered with oxytocin, individuals showing reduction of log-PDFmode of neutral facial expression from baseline to 2 weeks and increase of log-PDFmode neutral facial expression from 2 to 6 weeks were classified as participants exhibiting a time-course change (c). d Plots show changes in plasma DMG levels during the 6-week administration of oxytocin or placebo. Bars indicate mean concentration change in each group

Back to article page

Molecular Autism

ISSN: 2040-2392